{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:33:01Z","timestamp":1793363581511,"version":"4.5.0"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":1991,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.<\/jats:p>","DOI":"10.1002\/ejhf.1920","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T14:04:21Z","timestamp":1590674661000},"page":"1945-1960","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":781,"title":["Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society"],"prefix":"10.1093","volume":"22","author":[{"given":"Alexander R.","family":"Lyon","sequence":"first","affiliation":[{"name":"Cardio-Oncology Service, Royal Brompton Hospital and Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susannah","family":"Stanway","sequence":"additional","affiliation":[{"name":"Breast Unit, Royal Marsden Hospital , Surrey ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Earl","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Sinai Health System, Mount Sinai Hospital , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Groarke","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Brigham & Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Royal Marsden Hospital and Institute of Cancer Research , London ,","place":["UK"]},{"name":"Department of Medical Imaging and Radiation Sciences, Monash University and Department of Medicine, Melbourne University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ling","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, National University Heart Centre, Singapore, National University Health System , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus S.","family":"Anker","sequence":"additional","affiliation":[{"name":"Division of Cardiology and Metabolism, Department of Cardiology, Charit\u00e9 and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for Cardiovascular Research), partner site Berlin and Department of Cardiology, Charit\u00e9 Campus Benjamin Franklin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University of Goettingen Medical Center , Goettingen ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK), partner site Goettingen , Goettingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Maack","sequence":"additional","affiliation":[{"name":"Comprehensive Heart Failure Center, University Clinic W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Pudil","sequence":"additional","affiliation":[{"name":"First Department of Medicine \u2013 Cardioangiology, Charles University Prague, Medical Faculty and University Hospital Hradec Kralove , Prague ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[{"name":"MedStar Heart and Vascular Institute, Georgetown University , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[{"name":"Ted Rogers Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[{"name":"University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Belenkov","sequence":"additional","affiliation":[{"name":"Sechenov Medical University , Moscow ,","place":["Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Service, Royal Brompton Hospital and Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Iakobishvili","sequence":"additional","affiliation":[{"name":"Department of Community Cardiology, Tel Aviv Jaffa District, Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron L.","family":"Sverdlov","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health, University of Newcastle and \u201cCancer and the Heart\u201d Program, Hunter New England LHD , Newcastle ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludhmila A.","family":"Hajjar","sequence":"additional","affiliation":[{"name":"Cardio-Oncology, Department of Cardio-Pneumology, University of S\u00e3o Paulo , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane V.S.","family":"Macedo","sequence":"additional","affiliation":[{"name":"Santa Cardio-Oncology, Santa Casa de S\u00e3o Paulo and Rede Dor S\u00e3o Luiz , S\u00e3o Paulo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Manisty","sequence":"additional","affiliation":[{"name":"Barts Heart Centre and University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fortunato","family":"Ciardiello","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, Luigi Vanvitelli University of Campania , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"University of Cyprus Medical School , Nicosia ,","place":["Cyprus"]},{"name":"Cardio-Oncology Clinic, Heart Failure Unit, \u201cAttikon\u201d University Hospital, National and Kapodistrian University of Athens Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Skouri","sequence":"additional","affiliation":[{"name":"Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center , Beirut ,","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Suter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Bern University Hospital, Inselspital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cardinale","sequence":"additional","affiliation":[{"name":"Cardioncology Unit, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Fradley","sequence":"additional","affiliation":[{"name":"University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Cornell","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechelaker","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milojkovic","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hammersmith Hospital, Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"de Lavallade","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, King\u2019s College Hospital , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[{"name":"University Heart Center, Department of Cardiology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.S.","family":"Coats","sequence":"additional","affiliation":[{"name":"University of Warwick , Warwick ,","place":["UK"]},{"name":"Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar M.","family":"Seferovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade , Belgrade ,","place":["Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. C.C. Iliescu\u2019 , Bucharest ,","place":["Romania"]},{"name":"University of Medicine Carol Davila , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sol","family":"Andres","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Service, Royal Brompton Hospital and Imperial College , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Wright","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital , Liverpool ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Cardiology Service, Cardio-Oncology Unit, La Paz University Hospital and IdiPAz Research Institute, Ciber CV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Plummer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University , Newcastle ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Center of Excellence, Washington University in St Louis , St Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,6]]},"reference":[{"key":"2026080800514839900_ejhf1920-bib-0001","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080800514839900_ejhf1920-bib-0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation: a report from the ESC Cardio-Oncology Council","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080800514839900_ejhf1920-bib-0003","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom \u2013 a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080800514839900_ejhf1920-bib-0004","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0005","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080800514839900_ejhf1920-bib-0006","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0007","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0008","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080800514839900_ejhf1920-bib-0009","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080800514839900_ejhf1920-bib-0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026080800514839900_ejhf1920-bib-0011","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0012","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0013","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","article-title":"Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy","volume":"36","author":"Cardinale","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026080800514839900_ejhf1920-bib-0014","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"2026080800514839900_ejhf1920-bib-0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080800514839900_ejhf1920-bib-0016","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","article-title":"The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study","volume":"22","author":"Lenihan","year":"2016","journal-title":"J Card Fail"},{"key":"2026080800514839900_ejhf1920-bib-0017","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1007\/s13277-015-4183-7","article-title":"Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients","volume":"37","author":"De Iuliis","year":"2016","journal-title":"Tumour Biol"},{"key":"2026080800514839900_ejhf1920-bib-0018","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"2026080800514839900_ejhf1920-bib-0019","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"2026080800514839900_ejhf1920-bib-0020","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0021","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","article-title":"Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma","volume":"8","author":"Szmit","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2026080800514839900_ejhf1920-bib-0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"2026080800514839900_ejhf1920-bib-0023","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026080800514839900_ejhf1920-bib-0024","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1023\/A:1011655503511","article-title":"Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer","volume":"12","author":"Gianni","year":"2001","journal-title":"Ann Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2011","journal-title":"Curr Cardiol Rev"},{"key":"2026080800514839900_ejhf1920-bib-0026","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080800514839900_ejhf1920-bib-0027","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2010.33.4730","article-title":"High risk of symptomatic cardiac events in childhood cancer survivors","volume":"30","author":"van der Pal","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0028","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdn728","article-title":"Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk","volume":"20","author":"Barrett-Lee","year":"2009","journal-title":"Ann Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0029","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165262","article-title":"Body surface area and baseline blood pressure predict subclinical anthracycline cardiotoxicity in women treated for early breast cancer","volume":"11","author":"Kotwinski","year":"2016","journal-title":"PLoS One"},{"key":"2026080800514839900_ejhf1920-bib-0031","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0032","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026080800514839900_ejhf1920-bib-0033","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0034","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1078155214567162","article-title":"Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study","volume":"22","author":"Gunaldi","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"2026080800514839900_ejhf1920-bib-0035","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0036","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","article-title":"Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer trial","volume":"26","author":"Perez","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0037","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008637","article-title":"Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction","volume":"7","author":"Nowsheen","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026080800514839900_ejhf1920-bib-0038","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0039","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a Herceptin adjuvant study cardiac marker substudy","volume":"35","author":"Zardavas","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0040","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0041","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","article-title":"Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer","volume":"18","author":"Tarantini","year":"2012","journal-title":"J Card Fail"},{"key":"2026080800514839900_ejhf1920-bib-0042","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005195","article-title":"Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis","volume":"95","author":"Jawa","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2026080800514839900_ejhf1920-bib-0043","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000353450","article-title":"The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population","volume":"86","author":"Adamo","year":"2014","journal-title":"Oncology"},{"key":"2026080800514839900_ejhf1920-bib-0044","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080800514839900_ejhf1920-bib-0045","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0046","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2009.04.011","article-title":"Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study","volume":"15","author":"Guglin","year":"2009","journal-title":"J Card Fail"},{"key":"2026080800514839900_ejhf1920-bib-0047","first-page":"190","article-title":"Cardiac side effects of trastuzumab in breast cancer patients \u2013 single centere experiences","volume":"17","author":"Huszno","year":"2013","journal-title":"Contemp Oncol (Pozn)"},{"key":"2026080800514839900_ejhf1920-bib-0048","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","article-title":"Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events","volume":"50","author":"Ewer","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026080800514839900_ejhf1920-bib-0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.6596","article-title":"Frequency and risk factors for tyrosine kinase inhibitor-associated cardiotoxicity","volume":"34","author":"Hurley","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0050","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0051","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"2026080800514839900_ejhf1920-bib-0052","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"Di Lorenzo","year":"2009","journal-title":"Ann Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0053","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jchf.2012.09.001","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026080800514839900_ejhf1920-bib-0054","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"2026080800514839900_ejhf1920-bib-0055","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0071","article-title":"Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study","volume":"14","author":"Kozloff","year":"2009","journal-title":"Oncologist"},{"key":"2026080800514839900_ejhf1920-bib-0056","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2026080800514839900_ejhf1920-bib-0057","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol"},{"issue":"15 Suppl","key":"2026080800514839900_ejhf1920-bib-0058","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/jco.2014.32.4_suppl.508","article-title":"Clinicopathologic factors associated with the development of sunitinib-induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Neiman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0059","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahlen","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026080800514839900_ejhf1920-bib-0060","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0061","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.clml.2017.07.006","article-title":"Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up","volume":"17","author":"Aghel","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026080800514839900_ejhf1920-bib-0062","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"2026080800514839900_ejhf1920-bib-0063","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3324\/haematol.2016.144949","article-title":"Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients","volume":"101","author":"Castagnetti","year":"2016","journal-title":"Haematologica"},{"key":"2026080800514839900_ejhf1920-bib-0064","first-page":"4","article-title":"Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma","volume":"3","author":"Chen","year":"2017","journal-title":"Cardiooncology"},{"key":"2026080800514839900_ejhf1920-bib-0065","author":"Gov.UK","year":"2011"},{"key":"2026080800514839900_ejhf1920-bib-0066","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0067","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"key":"2026080800514839900_ejhf1920-bib-0068","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"\u2018Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma \u2013 analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"},{"key":"2026080800514839900_ejhf1920-bib-0069","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2026080800514839900_ejhf1920-bib-0070","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"2026080800514839900_ejhf1920-bib-0071","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11\u2009years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"2026080800514839900_ejhf1920-bib-0072","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in renal cancer","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080800514839900_ejhf1920-bib-0073","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"2026080800514839900_ejhf1920-bib-0074","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"2026080800514839900_ejhf1920-bib-0075","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2019.04.051","article-title":"Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention","volume":"288","author":"Caocci","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026080800514839900_ejhf1920-bib-0076","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","article-title":"The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia","volume":"1","author":"Fox","year":"2017","journal-title":"Blood Adv"},{"key":"2026080800514839900_ejhf1920-bib-0077","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","article-title":"Clinical features of pulmonary arterial hypertension in patients receiving dasatinib","volume":"90","author":"Shah","year":"2015","journal-title":"Am J Hematol"},{"key":"2026080800514839900_ejhf1920-bib-0078","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0079","article-title":"Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"2026080800514839900_ejhf1920-bib-0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026080800514839900_ejhf1920-bib-0081","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026080800514839900_ejhf1920-bib-0082","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026080800514839900_ejhf1920-bib-0083","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026080800514839900_ejhf1920-bib-0084","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/bju.12732","article-title":"The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study","volume":"114","author":"Gandaglia","year":"2014","journal-title":"BJU Int"},{"key":"2026080800514839900_ejhf1920-bib-0085","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2026080800514839900_ejhf1920-bib-0086","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080800514839900_ejhf1920-bib-0087","first-page":"200","article-title":"Transient apical ballooning syndrome during dobutamine stress echocardiography","volume":"26","author":"Martinez-Quintana","year":"2014","journal-title":"Clin Investig Arterioscler"},{"key":"2026080800514839900_ejhf1920-bib-0088","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"2026080800514839900_ejhf1920-bib-0089","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.1920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.1920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.1920","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/11\/1945\/66110897\/eurjhf_22_11_1945.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/22\/11\/1945\/66110897\/eurjhf_22_11_1945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:52:07Z","timestamp":1786164727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/22\/11\/1945\/8384579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,6]]},"references-count":89,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,8,6]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.1920","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,8,6]]},"assertion":[{"value":"2020-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}